Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT 1) receptor: Possible role of AT1 receptor dimerization

Cardiovascular Research

Volumn 79, Issue 1, 2008, Pages 169-178

  Yamada, Masahiro ^a   Kushibiki, Motoi ^a   Osanai, Tomohiro ^a   Tomita, Hirofumi ^a   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Aldosterone; AT1 receptor; Dimer; Vasoconstriction

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; EPLERENONE; MIFEPRISTONE; SPIRONOLACTONE; VALSARTAN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DRUG ACTIVITY; DRUG EFFECT; KNOCKOUT MOUSE; MALE; MICROSCOPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; WILD TYPE;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ARTERIOLES; BENZIMIDAZOLES; DIMERIZATION; MALE; MESENTERY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, ANGIOTENSIN, TYPE 1; SPIRONOLACTONE; TETRAZOLES; TRANSGLUTAMINASES; VALINE; VASOCONSTRICTION; VASODILATION;

EID: 45849093226     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn064     Document Type: Article

References (40)

1. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810.
2. Young MJ, Funder JW. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. J Hypertens 2002;20:1465-1468.
3. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-1364.
4. Wehling M. Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. J Mol Med 1995;73:439-447.
5. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003;14:2255-2263.
6. Fujita M, Minamino T, Asanuma H, Sanada S, Hirata A, Wakeno M et al. Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension 2005;46:113-117.
7. 2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 2005;146:973-980.
8. Schmidt BMW, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A et al. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 2003;42:156-160.
9. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003;166:345-349.
10. Wehling M, Spes CH, Win N, Janson CP, Schmidt BMW, Theisen K et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998;83:3517-3522.
11. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992;20:67-73.
12. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C et al. Aldosterone potentiates angiotensin II-Induced signaling in vascular smooth muscle cells. Circulation 2004;109:2792-2800.
13. 1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999;33:981-986.
14. Kushibiki M, Yamada M, Oikawa K, Tomita H, Osanai T, Okumura K. Aldosterone causes vasoconstriction in coronary arterioles of rats via angiotensin II type-1 receptor: Influence of hypertension. Eur J Pharmacol 2007;572:182-188.
15. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004;6:499-506.
16. AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U. Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 2004;119:343-354.
17. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 1995;270:18719-18722.
18. Duling BR, Gore RW, Dacey RG Jr, Damon DN. Methods for isolation, cannulation, and in vitro study of single microvessels. Am J Physiol 1981;241:H108-H116.
19. Kuo L, Chilian WM, Davis MJ. Interaction of pressure- and flow-induced responses in porcine coronary resistance vessels. Am J Physiol 1991;261:1706-1715.
20. + channels. Circulation 2001;103:1992-1998.
21. Zhang J, Lesort M, Guttmann RP, Johnson GVW. Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J Biol Chem 1998;273:2288-2295.
22. Wehling M, Kasmayr J, Theisen K. Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway? Am J Physiol 1991;260:E719-E726.
23. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-139.
24. Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T et al. Mineralocorticoid receptor blocker increases angiotensin- converting enzyme 2 activity in congestive heart failure patients. Circ Res 2005;97:946-953.
25. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993;91:1269-1281.
26. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser AH. Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 2005;46:701-706.
27. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005;97:434-442.
28. Chen X, Li W, Yoshida H, Tsuchida S, Nishimura H, Takemoto F et al. Targeting deletion of angiotensin type 1B receptor gene in the mouse. Am J Physiol 1997;272:F299-F304.
29. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000;407:94-98.
30. 1 receptor antagonist. J Biol Chem 2001;276:39721-39726.
31. Barki-Harrington L, Luttrell LM, Rockman HA. Dual inhibition of β-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 2003;108:1611-1618.
32. 1 receptor interaction in spontaneously hypertensive rats. Hypertension 2003;42:787-792.
33. 1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001;7:1003-1009.
34. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J 1991;5:3071-3077.
35. 2+ in vascular smooth muscle cells. Circ Res 1995;76:973-979.
36. Miura S, Kiya Y, Kanazawa T, Imaizumi S, Fujino M, Matsuo Yet al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive-state. Mol Endocrinol 2008;22:139-146.
37. Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006;281:19288-19295.
38. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005;14:235-241.
39. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
40. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.